![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 1.59% | 32.00 | 31.00 | 33.00 | 32.00 | 31.50 | 31.50 | 146,816 | 08:39:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0449 | -7.13 | 22.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/7/2024 14:55 | The post below (from LSE) clearly not in reality PMSL 🤣 👇 My answers below his: Leggster Posts: 339 Price: 33.00 No Opinion News FlowToday 12:58 Despite the attempts to misdirect by some, we can expect news and it will arrive in due course - topline safety results being shared Yep we know, Safety data is one thing. We still don't know if 1801 works! 🤦🏻 - Way forward for 1801 Perhaps 1801 will go backwards in the next Phase of the clinical trial? - 737 update Are you kidding me. 737 is all if, buts or maybes - absolutely no idea if it works. Currently NO revenue. GSK didn't want it. - possible license deal for 1801 (possibly including 1802) No hint at all of licensing or take over deals. I'm sorry, but you're clearly living in cloud cuckoo land and are over excited - there ARE NO DEALS! - Possible takeover See answer above - future plans for 1802 There're no future plans at present! - Possible VC stake 😂 - New CEO And? GLA Your going to need it!! | ![]() peaceandlove | |
24/7/2024 14:55 | Look at that share price fall.. Time to short some more... | ![]() wolfofwallstreets | |
24/7/2024 12:26 | Great post on lse.. I have to agree with you FunnyGuy, SOG spends day and night writing reams of stuff that frankly I can't be bothered to read. This is normally followed by his mate Celtic backing up everything he's written and calling anyone else with an alternative opinion a tw*t. If only I had a penny every time I read on here "news soon". | ![]() wolfofwallstreets | |
24/7/2024 07:35 | Another day goes by and no news. The reason there's no news is because there isn't any. As per usual, the happy clappers use their imagination, put 2+2 together and get 5! There're no license or takeover deals on the horizon IMO. If there was they'd need to be disclosed. Assuming the results are satisfactory, my hunch is they'll announce a placing and it'll go on and on..... I said many times Clinical trials are very expensive. There is no guarantee Sareum will succeed and with 90% of clinical trials failing the odds are against them. So many unanswered questions with this company. | ![]() peaceandlove | |
23/7/2024 19:59 | Any imaginary takeovers happen today?! Or imaginary licence deals?! Or "deals in our sector..." Bunch of ramping clowns... Rns soon for more cash.... | ![]() wolfofwallstreets | |
23/7/2024 16:16 | Honestjon is just sadoldfart from lse... Ramping clown.. | ![]() wolfofwallstreets | |
23/7/2024 15:59 | Not sure what happy clsppy is? Possibly because you can’t coordinate a clap? Clown | ![]() honestjon | |
23/7/2024 15:13 | Hahaha... "Sareum will triumph this year".. (c) 2020, 2021, 2022, 2023, 2024 Away you go, you happy clsppy ramper.. | ![]() wolfofwallstreets | |
23/7/2024 12:01 | Sareum will triumph this year. | ![]() honestjon | |
23/7/2024 09:05 | Sareum will collapse this year... | ![]() wolfofwallstreets | |
22/7/2024 22:21 | No wolf its in the rns that GSK are holders of SRA737 I can't unfortunately say that's you are wrong .but you are Lse are digging their own grave if they ignore my posts .shame...but interesting with strategic reasons..I hold more than them..even Shepherd...nothing by association with a similar name involved in trust funds...I got contacted by an lse poster...but hold my own. | ![]() criticalthinker1 | |
22/7/2024 22:01 | "Ground breaking info.." So full of it.. You post copy and paste garbage that nobody reads... You're a fool... Sareum.will die by year end... | ![]() wolfofwallstreets | |
22/7/2024 21:53 | Criticalstinker...do you have dementia?! You're the genius who said 737 was being returned so gsk could launch a takeover... You can't even remember the garbage you come out with... Let me have a rummage... | ![]() wolfofwallstreets | |
22/7/2024 21:05 | The only possible concern I have wolf is my posts get no upticks...so despite my posts being on point I wonder if certain posters on lse are working this company for their own benefit...food for thought...shame if its true...would make sense given the ground breaking info I've put forward... That would make pcs sog indirect rampers...because they say multiple times about advfn posters but fail to recognise my input...hmmmmmmm | ![]() criticalthinker1 | |
22/7/2024 20:59 | Interesting you keep talking about takeover as opposed to onlicense...personal | ![]() criticalthinker1 | |
22/7/2024 20:40 | Criticalstinker... Great post...didn't read a word... You're dreaming your life away... When's the takeover... | ![]() wolfofwallstreets | |
22/7/2024 19:21 | Not sure billions of shares, unless multiple buying and selling....however, it's worth remembering that the introducers have warrants outstanding as do some of HNWIS..but not enough to make the share count...billions...m But food for thought In late 2021, Sierra had indicated revived interest in developing SRA737 as a potential combination therapy (in both haematological malignancies and solid tumours) following its in-licensing of the BET inhibitor AZD5153 (now known as SRA515) from AstraZeneca (August 2021). As per our understanding, Sierra was in the process of finalising trial designs for the three possible studies assessing SRA737 as a combination treatment, before receiving the offer from GSK. Now I've proven that SRA737 has continued in its progress...I feel the newly shuffled board might address this. Atleast they surely have to. Just wonder if Blenrep got a helping hand...and not forgetting that AZ got involved with AZD 5153...aka SRA515...dexamethaso So my muse. .. GSK have now a carte blanche and have the means to undertake a clean break with their pharma side since Haleon now independent...but would love to bring a company into its fold that have multiple patents in the USA and China and Europe...I believe pending...with THE ipr that is required...imo...Wil All best Steadydanny And yes the investment into cytokine storms and cytotoxicity is imo of very a noteable requirement...citize Nevertheless, we can all have our opinions snd those hopefully backed by research...we can always DREAMM-8... | ![]() criticalthinker1 | |
22/7/2024 18:48 | How do you mean?? | ![]() wolfofwallstreets | |
22/7/2024 17:28 | In few days billions of the share going to exchange | ![]() hamidmontana | |
22/7/2024 09:33 | Sadoldtart is so stupid that he still calls this BB "ADVN"... Utter moron.. "Good morning c79..great post from you as usual".. As you're just another subservient agreeable ramping fool who agrees with me ... | ![]() wolfofwallstreets | |
22/7/2024 08:10 | Sadoldtart being rinsed again on lse... Utter ramping moron.. | ![]() wolfofwallstreets | |
21/7/2024 20:34 | Wolf, take note of Bobblers post on LSE. The average retail price for Sotyktu is $8,348.71 per 30, 6MG Tablet. Looks like those tyk2’s do have a value. No guarantee Sar have it cracked, but certainly looks like a decent gamble. | ![]() honestjon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions